GI
ZNTL icon

GAMMA Investing’s Zentalis Pharmaceuticals ZNTL Stock Holding History

GAMMA Investing’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2
Closed -$8 – 3655
2024
Q2 		$8 Sell
2
-24
-92% -$268 ﹤0.01% 3442
2024
Q1 		$410 Buy
26
+7
+37% +$96 ﹤0.01% 3134
2023
Q4 		$225 Buy
+19
New +$277 ﹤0.01% 3111

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

GAMMA Investing's ZNTL Position: Q3 2024 in Review

GAMMA Investing sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 2 shares — an estimated $8 sold.

GAMMA Investing first reported a position in ZNTL in Q4 2023 and held it in 3 quarters. The position peaked at $410 in Q1 2024. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • GAMMA Investing reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • GAMMA Investing sold 2 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $8.
  • GAMMA Investing first reported a position in Zentalis Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • GAMMA Investing's Zentalis Pharmaceuticals position peaked at $410 in Q1 2024.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on GAMMA Investing's 13F filing for Q3 2024, filed 7 Oct 2024.